The FDA regulates products that account for one-fifth of American consumer spending—everything from lettuce to vapes to pet ...

Schrodinger has won U.S. Food and Drug Administration fast-track designation for its SGR-1505 drug candidate in a rare type of non-Hodgkin's lymphoma.

The Food and Drug Administration announced the launch of a new program to fast-track agency approvals for drug manufacturers ...

June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as ...

The Commissioner's National Priority Voucher (CNPV) programme will be available to companies aligned with pressing matters ...

The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis, which ...

FNP-223 is currently being investigated in a phase 2 trial evaluating the treatment in adults with possible or probable PSP-Richardson syndrome.

US regulators, under the guidance of FDA Commissioner Marty Makary, are launching a program to accelerate drug approvals, ...

Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug ...

The FDA has granted Fast Track designation to nadunolimab to treat patients with previously untreated metastatic pancreatic ductal adenocarcinoma.

The Food and Drug Administration announced the launch of a new program to fast-track agency approvals for drug manufacturers working on products that could cure chronic disease, prepare for a ...